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440Objective: Adenosine and the activation of specific adenosine receptors are implicated in the attenuation of
inflammation and organ ischemia-reperfusion injury. We hypothesized that activation of A1, A2A, or A3 adeno-
sine receptors would provide protection against lung ischemia-reperfusion injury.
Methods:With the use of an isolated, ventilated, blood-perfused rabbit lung model, lungs underwent 18 hours of
cold ischemia followed by 2 hours of reperfusion. Lungs were administered vehicle, adenosine, or selective A1,
A2A, or A3 receptor agonists (CCPA, ATL-313, or IB-MECA, respectively) alone or with their respective antag-
onists (DPCPX, ZM241385, or MRS1191) during reperfusion.
Results: Compared with the vehicle-treated control group, treatment with A1, A2A, or A3 agonists significantly
improved function (increased lung compliance and oxygenation and decreased pulmonary artery pressure),
decreased neutrophil infiltration by myeloperoxidase activity, decreased edema, and reduced tumor necrosis fac-
tor-a production. Adenosine treatment was also protective, but not to the level of the agonists. When each agonist
was paired with its respective antagonist, all protective effects were blocked. The A2A agonist reduced pulmonary
artery pressure and myeloperoxidase activity and increased oxygenation to a greater degree than the A1 or A3
agonists.
Conclusion: Selective activation of A1, A2A, or A3 adenosine receptors provides significant protection against
lung ischemia-reperfusion injury. The decreased elaboration of the potent proinflammatory cytokine tumor necro-
sis factor-a and decreased neutrophil sequestration likely contribute to the overall improvement in pulmonary
function. These results provide evidence for the therapeutic potential of specific adenosine receptor agonists in
lung transplant recipients. (J Thorac Cardiovasc Surg 2010;140:440-6)Primary graft dysfunction (PGD), the most severe form of
ischemia-reperfusion (IR) injury, continues to be a major
cause of morbidity and mortality after lung transplantation.
The most recent report from the International Society for
Heart and Lung Transplantation reported that PGD was the
leading cause of death (28.8% of patient deaths) within the
first 30 days after transplant.1 Although the overall incidence
of lung IR injury has remained fairly constant (<25%), the
30-day mortality after transplant has improved over the past 2
decades primarily because of reductions in PGD.2 The clinical
significance of lung IR injury is further magnified by its asso-
ciation with the development of bronchiolitis obliterans.3 Im-
proving outcomes after lung transplantation and extending thee Departments of Surgerya and Medicine,b University of Virginia Health Sys-
harlottesville, Va.
dy was supported by National Institutes of Health R01HL092953 (to V.E.L.
L.K.), National Institutes of Health T32HL007849 (to I.L.K.), and the Roche
Transplant Research Foundation (to V.E.L.).
res: Drs Linden and Kron were shareholders in Adenosine Therapeutics,
the corporation that provided ATL-313, at the time of the study.
d for publication Aug 20, 2009; revisions received Dec 8, 2009; accepted for
ation March 1, 2010; available ahead of print April 16, 2010.
for reprints: Victor E. Laubach, PhD, Department of Surgery, University of
nia Health System, PO Box 801359, Charlottesville, VA 22908 (E-mail:
ch@virginia.edu).
23/$36.00
ht  2010 by The American Association for Thoracic Surgery
016/j.jtcvs.2010.03.002
The Journal of Thoracic and Cardiovascular Surgdonor pool and recipient criteria are predicated on the ability
tominimize the deleterious inflammatory responses that occur
with lung IR injury.
Adenosine is an endogenous mediator that typically serves
as a cytoprotective modulator in response to stress. Many
studies have demonstrated the protective effects of adenosine
in the setting of organ IR injury. Adenosine signals through 4
subtypes of the G protein-coupled receptor, A1, A2A, A2B, and
A3, all of which are expressed in the lung. Protective effects of
adenosine receptor signaling classically occur through second
messenger pathways, such as cAMP production or the phos-
pholipase C pathway. Our laboratory has extensively studied
selective A2A receptor activation and shown it to provide sig-
nificant protection against lung IR injury.4-6 However, the
effects of specific activation of A1, A2B, and A3 adenosine
receptors in lung IR injury remain poorly understood.
Previous studies have provided evidence that A1 and A3
receptors may primarily be involved in anti-inflammatory ac-
tions,7,8 whereas the A2B receptor may have more
proinflammatory actions9 in the lung. The objective of this
study is to further define the protective effects of adenosine re-
ceptor subtypes, using specific agonists and antagonists, on
lung IR injury. We hypothesize that specific activation of
A1, A2A, or A3 receptors provides significant protection
from lung injury and dysfunction after IR. The use of specific
adenosine receptor agonists and antagonists in an isolated,ery c August 2010
Abbreviations and Acronyms
BAL ¼ bronchoalveolar lavage
IR ¼ ischemia-reperfusion
MPO ¼ myeloperoxidase
PA ¼ pulmonary artery
PGD ¼ primary graft dysfunction
TNF-a ¼ tumor necrosis factor-alpha
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Xblood-perfused rabbitmodel of lung IRwill be used to test this
hypothesis.
MATERIALS AND METHODS
Animal Care
New Zealand white rabbits (Burleson Enterprises, Inc, Unionville, Va)
of both genders (3.0-3.5 kg) were used in this study and received humane
care in accordance with the ‘‘Guide for Care and Use of Laboratory
Animals,’’ published by the National Institutes of Health (publication no.
85-23, revised 1995). The study protocol was reviewed and approved by
the animal care and use committee at the University of Virginia.
Experimental Protocol
Eight experimental groups of lungs (n ¼ 6/group) were compared using
an isolated, whole-blood perfused, ventilated rabbit lung model of IR (Kent
Scientific, Model TIS3862, Litchfield, CT) as previously described.4 All
lungs were reperfused for 120 minutes after 18 hours of cold ischemic stor-
age, time periods that we previously demonstrated to result in reproducible
injury versus sham lungs.4 Lungs received vehicle (dimethylsulfoxide),
adenosine, or a specific adenosine receptor agonist (with or without its
respective antagonist), as summarized in Table 1. Each agonist used in
this study is potent and specific for its target: IB-MECA is reported to be
approximately 50-fold selective for A3 versus A1 or A2A;
10 ATL-313 is
selective for A2A versus A1 (81-fold) and A3 (350-fold);
11 and CCPA is re-
ported to be approximately 53-fold selective for A1 versus A2A or A3.
12
Each receptor agonist or antagonist was added to the whole-blood perfusate
at the beginning of reperfusion (see Table 1 for specific doses). The doses
used were based on well-established doses used in previous studies and
do not result in significant cardiovascular effects.4,13,14 Adenosine was
administered by constant infusion (0.75 mg/kg/min) during reperfusion
because of its short half-life of several seconds in whole blood.
Harvest Procedure
Animals were randomly assigned to each experimental group. Each
animal was anesthetized with intramuscular ketamine (50 mg/kg) and xyla-
zine (5 mg/kg). Tracheal intubation was performed via a tracheostomy, and
mechanical ventilation (Kent Scientific, Model RSP1002) was instituted
with room air at a respiratory rate of 30 breaths/min. Median sternotomy
and thymectomy were performed. The aorta and pulmonary artery (PA)
were encircled, and 1000 U/kg heparin was administered intravenously.
Prostaglandin E1 (30 mg) was then administered via the PA, and the vena
cavae were ligated to initiate ischemia 5 minutes after heparin administration.
The PA was then cannulated through a ventriculotomy made within a purse-
string placed in the right ventricular outflow tract. After the left ventricle was
vented through a left ventriculotomy and the aorta was ligated, 100 mL/kg of
buffered Perfadex (Vitrolife, Kungsbacka, Sweden) preservation solution
was infused into the PA at a pressure of 30 cm H2O at 4
C. Topical cooling
was achieved with cold saline solution slush. The left atrium was cannulated
through the left ventriculotomy with an outflow catheter. The lung–heart
block was excised. The lungs were stored inflated at 4C for 18 hours.The Journal of Thoracic and CaReperfusion Procedure
A force transducer suspended the heart–lung block, and ventilation was
initiated with a 95% oxygen and 5% carbon dioxide gas mixture (Kent
Scientific, Model RSP1002). All groups underwent 120 minutes of
whole-blood perfusion at 37C. Atelectasis was grossly eliminated by ad-
ministering 1 breath of approximately 30 cm H2O positive end-expiratory
pressure once per minute during the first 5 minutes of the stabilization pe-
riod. Lungs were ventilated at a constant tidal volume of 10 mL/kg with 3
cm H2O of positive end-expiratory pressure at a rate of 30 breaths/min.
The PA and outflow catheters connected the lung–heart block to a venous
blood reperfusion circuit. New Zealand white rabbits served as fresh venous
blood donors. Bloodwas circulated through a pediatric oxygenator set to de-
oxygenate the blood and add carbon dioxide to simulate venous blood
(PO2 ¼ 60 mm Hg/PCO2 ¼ 60 mm Hg). The lungs were subsequently per-
fused via the PA cannula at 60 mL/min with ‘‘venous’’ blood at 37C.
Lung Physiology
A dynamic data acquisition program (DASYLab; DASYTEC, USA,
Bedford, NH) recorded PA pressure and pulmonary compliance. Pulmonary
venous blood samples were collected for blood gas analysis (Bayer 348 pH/
Blood Gas Analyzer; Bayer Corp, E Walpole, Mass) at 15, 30, 60, 90, and
120 minutes after initiation of reperfusion.
Lung Wet/Dry Weight
The lung wet/dry weight ratio was used to assess pulmonary edema. Af-
ter the 120-minute reperfusion period, fresh samples of lung tissue were col-
lected from the right lower lobe of the left lung. Fresh lung samples were
blotted to remove excess blood; they were then weighed and desiccated un-
der vacuum at 55C until a stable dry weight was achieved.
Myeloperoxidase Activity
Neutrophil sequestration was assessed by measuring myeloperoxidase
(MPO) activity in left lung tissue, as previously described by our laboratory.5
Bronchoalveolar Lavage
Bronchoalveolar lavage (BAL)was performed on all lungs at the end of the
reperfusion period. The right upper and middle lobes were isolated and lav-
aged with 10 mL normal saline. The BAL fluid was then centrifuged at
1500g for 5minutes at 4C.The supernatantwas storedat80Cuntil analysis.
Measurement of Tumor Necrosis Factor-a
Protein levels of tumor necrosis factor (TNF)-a in BAL fluid were mea-
sured using a TNF-a enzyme-linked immunosorbent assay kit (BD Biosci-
ences, San Diego, Calif) as instructed by the manufacturer. Samples were
assessed in triplicate.
Statistics
Values are expressed as the mean standard error of the mean. Analysis
of variance was used to determine whether significant differences existed
among the groups. Tukey’s honestly significant difference multiple-
comparison test was used to determine which groups were significantly
different when the analysis of variance results were significant. Repeated-
measures analysis of variance was performed and ultimately allowed us
to conclude that PA pressure, lung compliance, and oxygenation changed
over time and depended on the group.
RESULTS
Lung Physiology
Selective activation of A1 and A2A receptors during reper-
fusion resulted in significant decreases in PA pressure versus
control at the end of the 120-minute reperfusion periodrdiovascular Surgery c Volume 140, Number 2 441
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TABLE 1. Adenosine receptor agonists and antagonists used
Adenosine
receptor
Agonist
(dose, source)
Antagonist
(dose, source)
A1 CCPA
(10 nM; Sigma, St Louis, Mo)
DPCPX
(100 nM; Sigma)
A2A ATL-313
(100 nM; Dr J. Linden)
ZM241385 (100 nM; Tocris
Bioscience, Ellisville, Mo)
A3 IB-MECA
(60 nM; Sigma)
MRS1191
(10 nM; Sigma)
All Adenosine
(0.75 mg/kg/min; Sigma)
NA
CCPA, 2-chloro-N(6)-cyclopentyladenosine; ATL-313, 4-{3-[6-amino-9-(5-cyclopro-
pylcarbamoyl-3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-pip
eridine-1-carboxylic acid methyl ester; IB-MECA, 2-chloro-N6-(3-iodobenzyl)
adenosine-5’-N-methyluronamide; DPCPX, 8-cyclopentyl-1,3-dipropylxanthine; ZM
241385, 4-(2-[7-Amino-2-[2-furyl][1,2,4]triazolo[2,3-a][1,3,5]triazin-5-yl-amino]-
ethyl); MRS 1191, 3-ethyl-5-benzyl-2-methyl-6-phenyl-4-phenylethynyl-1, 4-
()-dihydropyridine-3,5-dicarboxylate.
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X(Figure 1, A). In addition, significant decreases in PA pres-
sure were observed in the A2A agonist-treated group relative
to treatment with A1 or A3 agonists (Figure 1, A). The A3 re-
ceptor agonist reduced PA pressure somewhat, but not sig-
nificantly. The A1, A2A, and A3 receptor agonists resulted
in significant increases in lung compliance (Figure 1, B)
and oxygenation (Figure 1, C) compared with control at
120 minutes of reperfusion. Oxygenation was significantly
higher in the A2A agonist-treated group versus treatment
with A1 or A3 agonists (Figure 1, C). The improvements in
the aforementioned physiologic measurements by each ago-
nist were all blocked by the concomitant administration of
antagonist (Table 2). Although adenosine administration re-
sulted in significant improvement of PA pressure, lung com-
pliance, and oxygenation, these improvements were
generally not as great as for the receptor agonists.520
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FIGURE 1. Lung function. Comparison of PA pressure (A), pulmonary
compliance (B), and oxygenation (C) among groups at the end of the
120-minute reperfusion period. *P<.0002 versus control. #P< .02 versusProduction of Tumor Necrosis Factor-a
TreatmentwithA1,A2A, andA3 receptor agonists, and aden-
osine resulted in significantly less production of the proinflam-
matory cytokine TNF-a versus control (Figure 2, A). The
administration of each receptor agonist with its respective
antagonist blocked the decrease in TNF-a (Table 3). No signif-
icant difference in TNF-a production occurred among the
agonist-treated groups. Each receptor agonist resulted in signif-
icantly lower TNF-a production compared with adenosine
alone.
adenosine. xP< .02. PA, Pulmonary artery.Myeloperoxidase Activity
MPO activity was used as an indicator of neutrophil
sequestration into the lung. Treatment with A1, A2A, and
A3 receptor agonists, and adenosine resulted in significant
decreases in MPO activity versus control (Figure 2, B).
The administration of each receptor agonist with its respec-
tive antagonist blocked the decrease in MPO activity
(Table 3). Selective A2A receptor activation resulted in the442 The Journal of Thoracic and Cardiovascular Surggreatest decrease in MPO activity (44% reduction vs con-
trol). Each receptor agonist resulted in significantly less
MPO activity compared with adenosine alone.
Wet/Dry Weight Ratio
Lung wet/dry weight ratio was measured to assess pulmo-
nary edema. Treatment with A1, A2A, and A3 receptorery c August 2010
TABLE 2. Pulmonary function at the end of the 120-minute reperfusion period
Group
PA pressure
(mm Hg)
Compliance
(cm H2O)
Oxygenation
(mm Hg)
Control 32.83  0.48 4.93  0.03 527.7  1.1
A1 agonist 24.17  1.19*,x 5.70  0.03*,y 551.7  2.2*,y
A1 agonistþantagonist 31.67  0.56y 5.07  0.03y 527.0  2.1
A2A agonist 18.50  0.62*,z,x 5.87  0.08*,y 569.2  1.1*,y,z,x
A2A agonistþantagonist 31.33  0.84y 5.12  0.48y 525.3  2.9y
A3 agonist 29.17  1.66y,z 5.85  0.04*,y 556.2  4.0*,y
A3 agonistþantagonist 32.00  1.59y 5.07  0.06y 530.0  3.5
Adenosine 21.67  0.49* 5.33  0.04* 538.3  2.5*
PA, Pulmonary artery. *P< .0002 vs control. yP< .02 vs adenosine. zP< .01 vs A1 agonist. xP< .02 vs A3 agonist.
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weight versus control (Figure 2, C). The administration of
each receptor agonist with its respective antagonist blocked
the decrease in wet/dry weight (Table 3). No significant dif-
ference in wet/dry weight occurred between the agonist- and
adenosine-treated groups.
DISCUSSION
Pharmacologic modulation of specific adenosine receptors
may be a useful therapeutic method for attenuating lung IR
injury, thus improving patient outcomes after lung transplan-
tation. Although the anti-inflammatory effects of adenosine
are well described, the ability to translate adenosine-related
therapeutics into clinical practice requires better understand-
ing of the relationship between adenosine receptor subtypes
and end-organ effect. The protective as well as deleterious
profile of adenosine receptors with respect to lung IR injury
is poorly understood. A modest number of studies have
begun to evaluate the role of single adenosine receptors in
lung IR injury.4,7,15 However, it is difficult to compare and
contrast the role of different adenosine receptor subtypes
between these various studies and models. The present
study better characterizes and compares the effects of
specific activation of A1, A2A, and A3 receptors in an
accepted, reproducible model of lung IR injury.
Of the adenosine receptor subtypes, A2A receptor activa-
tion has most consistently demonstrated potent anti-
inflammatory properties and has repeatedly attenuated lung
IR injury in various studies. For example, A2A agonists
have been associated with inhibition of inflammatory cyto-
kine release, reduction of IR-induced apoptotic injury, and
diminution of free radical production.4,16 In addition,
neutrophil-induced IR injury is directly abrogated by selec-
tive A2A receptor activation.
17 The attenuation of lung
dysfunction and injury after IR by A2A agonists observed
in prior studies was confirmed in the present study. Com-
pared with A1 and A3 receptor agonists, the A2A agonist pro-
vided greater protection (eg, lower PA pressure, improved
oxygenation, and reduced MPO activity), possibly because
A2A receptors are predominantly expressed on inflammatory
cells, including neutrophils, mast cells, macrophages, mono-The Journal of Thoracic and Cacytes, and T cells. It has been shown that A2A receptor acti-
vation prevents leukocyte adhesion to endothelial cells and
inhibits the release of toxic oxygen products.18
Studies on the role of A1 receptor activation in lung IR in-
jury have been somewhat confusing. Although the A1 recep-
tor has been shown to play a protective role after IR in the
heart,19 intestine,20 liver,8 and kidney,21 an early study by
Neely and Keith15 concluded that A1 receptor antagonists
block lung IR injury. Paradoxically, A1 receptor activation
with CCPA was shown to exert a cytoprotective role against
IR injury in skeletal muscle, an effect that was blocked by
the A1 receptor antagonist DPCPX.
22 In the current study,
A1 receptor activation by CCPA improved lung function
in association with decreased neutrophil infiltration (MPO
activity), inflammatory cytokine production (TNF-a), and
edema (wet/dry weight). Notably, these protective effects
were blocked by DPCPX. One possible explanation for the
differing conclusions between our study and Neely and
Keith’s study could involve differences in the model. Neely
and Keith used an in vivo model in which the left lower lobe
in cats with intact chests was rendered ischemic for 2 hours
and reperfused for 2 hours. A more likely explanation could
involve a difference in DPCPX administration: We used
DPCPX at a concentration of 100 nM in the whole-blood
reperfusate, whereas Neely and Keith used a bolus dose of
6 mg/kg DPCPX to the cat either 30 minutes before ischemia
or 1 hour after reperfusion. We estimate that this dose
resulted in a blood concentration of DPCPX at least 700-
fold greater than our dose of 100 nM, a dose that could
lead to unwanted side effects, such as the nonspecific antag-
onism of other (anti-inflammatory) adenosine receptors. Al-
though 100 nM DPCPX was efficient in blocking the
protective effects of the A1 agonist CCPA in our study,
we did not test the effect of DPCPX alone.
Proinflammatory properties of the A3 receptor have been
demonstrated by mast-cell degranulation resulting from ad-
ministration of IB-MECA.23 On the other hand, A3 receptor
activation reduces degranulation and free radical formation
from eosinophils.24More anti-inflammatory effects, however,
have been associated with A3 receptor activation. For exam-
ple, activation of the A3 receptor was shown to suppressrdiovascular Surgery c Volume 140, Number 2 443
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FIGURE 2. Lung injury. Comparison of TNF-a levels in BAL fluid (A),
MPO activity (B), and lung wet/dry weight ratio (C) among groups at the
end of the 120-minute reperfusion period. *P < .0002 versus control.
#P < .01 versus adenosine. xP < .01. TNF-a, Tumor necrosis factor;
MPO, myeloperoxidase.
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Xsuperoxide production and chemotaxis in mouse neutro-
phils.25 Moreover, various studies have demonstrated that
A3 agonists reduce IR-associated myocardial injury.
26,27 In
a study of feline lung IR injury, Rivo and colleagues7 showed
that A3 receptor activation with IB-MECA reduced alveolar
injury, wet/dry weight, MPO activity, and apoptosis. In sup-
port of these data, the current study found that IB-MECA pro-444 The Journal of Thoracic and Cardiovascular Surgvided significant protection against lung dysfunction and
injury after IR. However, A3 receptor activation differed
from A1 and A2A receptor activation in that it did not signifi-
cantly decrease PA pressure versus control.
The administration of adenosine during reperfusion re-
duced PA pressure and increased lung compliance and oxy-
genation. The A1, A2A, and A3 receptor agonists all
improved oxygenation and lung compliance to a greater ex-
tent than adenosine alone. Although adenosine infusion did
decrease TNF-a production and MPO activity versus con-
trol, this was not as great a decrease as observed with the
A1, A2A, and A3 agonists. This may account for the poorer
lung function with adenosine treatment compared with the
agonists. Adenosine has also been shown to enhance the
release of histamine from mast cells and potentiate the bron-
choconstrictor response in patients with chronic obstructive
pulmonary disorder and asthma.24 Interactions and cross-
talk between the adenosine receptors themselves also remain
largely unknown and might account for differences in end-
organ effect between adenosine administration and selective
adenosine receptor activation. Finally, adenosine could also
be activating the A2B receptor, a pathway that may be proin-
flammatory in this setting.
Although small but significant differences in oxygenation
were observed as summarized, all of the PO2 levels were
greater than 500 mm Hg. This high degree of oxygenation
would likely not make a large clinical difference. However,
we reported PO2 levels in this study to complete the data and
illustrate that the observed significant differences in oxygen-
ation correlated well with other differences in physiologic
parameters, such as PA pressure and pulmonary compliance.
As stated in the ‘‘Materials and Methods’’ section, the
doses of agonist used in our study were based on well-
established doses used in previous studies and do not result
in significant cardiovascular effects. Thus, it is unlikely that
the protective effects of the agonists were primarily physio-
logic. The reductions in PA pressure observed with the use
of the agonists are likely secondary to the anti-inflammatory
affects of the agonists. The mechanism responsible for these
anti-inflammatory effects is not completely understood.
Adenosine receptors couple, via G proteins, to an intricate
network of second messenger signaling pathways, such as
modulation of cAMP production or phospholipase C. How-
ever, the effects of G protein coupling can differ substantially
between receptor subtypes. In addition, they are known to
couple to mitogen-activated protein kinases, indicating a pos-
sible role in cell growth, differentiation, survival, and death.
Current studies in our laboratory are evaluating mechanisms
of action and what cell types are most responsible for the pro-
tective effects of adenosine receptors in the setting of lung IR
injury.
The role of the A2B receptor in lung IR injury remains
largely unknown because no selective, potent A2B agonists
yet exist. Functional A2B receptors are widely distributedery c August 2010
TABLE 3. Pulmonary inflammation at the end of the 120-minute reperfusion period
Group
TNF-a
(pg/mL)
MPO Activity
(DOD/g/min) Wet/dry weight
Control 1336  18.9 0.858  0.012 3.07  0.08
A1 agonist 759  14.7*,y 0.582  0.013*,y 2.22  0.05*
A1 agonistþantagonist 1308  18.7y 0.810  0.015y 2.98  0.09y
A2A agonist 804  17.6*,y 0.482  0.017*,y,z 2.08  0.05*
A2A agonistþantagonist 1326  18.7y 0.847  0.026y 2.90  0.18y
A3 agonist 778  10.5*,y 0.540  0.016*,y 2.03  0.08*
A3 agonistþantagonist 1287  13.8y 0.843  0.150y 3.00  0.06y
Adenosine 978  26.0* 0.697  0.028* 2.41  0.06*
TNF-a, Tumor necrosis factor; MPO, myeloperoxidase. *P< .0002 vs control. yP< .01 vs adenosine. zP< .01 vs A1 agonist.
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topoietic cells, mast cells, and endothelium,28 and have
recently been shown to be highly expressed on mouse alve-
olar epithelial cells.29 Activation of A2B receptors has been
associated with the release of proinflammatory mediators
by activated human mast cells and subsequent release of
interleukin-8.30 In addition, results from Sun and col-
leagues9 suggest that A2B receptor signaling influences path-
ways critical for pulmonary inflammation and injury in vivo.
With the recent development of A2B receptor knockout
mice, the role of the A2B receptor in lung injury will be better
understood. In fact, our laboratory has observed that A2B
receptor knockout mice have less lung injury after IR com-
pared with wild-type mice (F. Anvari, MD, unpublished
data, May 2010), further supporting a proinflammatory
role of the A2B receptor in lung injury.
Study Limitations
The current study has several limitations. One limitation
of the isolated rabbit lung model is in the length of study.
It is difficult to perfuse the lungs beyond 2 hours and main-
tain stable lungs, and thus we limited the reperfusion time to
2 hours. However, we think the acute period of reperfusion
(ie, the first several hours) is a critical time of injury that
determines whether a transplant recipient will experience
PGD, which is why we focused on this acute time period.
It is possible that longer reperfusion times might lead to
different results, and we speculate that some of the parame-
ters used to assess lung protection by adenosine receptor ag-
onists, such as oxygenation, would be even more convincing
after longer reperfusion.
Another limitation is that we did not use any mechanical
maneuvers, such as controlled low-pressure reperfusion,
which is often used in the clinical setting. One reason for
this is because we wanted to remain consistent with the
model used in our previous studies, which produces signif-
icant and reproducible injury. It is possible that such me-
chanical maneuvers would mask the protection offered by
adenosine receptor agonists. However, despite such maneu-
vers used in transplant recipients, there will always be some
level of inflammation induced on reperfusion. It is likely thatThe Journal of Thoracic and Caa combination of mechanical maneuvers and adenosine re-
ceptor agonists would prove most effective at preventing
both immediate endothelial injury and inflammation, as
well as later injury and infiltration of inflammatory cells.
One of the goals of our study was to directly compare the
protective effects of the different adenosine agonists.
Some of these differences were small but significant, and
these differences may not have been detected if we had
used mechanical maneuvers to blunt injury.CONCLUSIONS
The results from the present study suggest that selective
activation of A1, A2A, or A3 adenosine receptors provides
protection after lung IR by significantly attenuating both
lung dysfunction and injury. As better adenosine receptor
agonists are developed and the interactions between adeno-
sine receptors are further elucidated, the pharmacologic
modulation of adenosine receptor signaling will likely play
an important role in minimizing the vast deleterious effects
of IR injury after lung transplantation. Further characteriza-
tion of protective as well as potentially detrimental effects of
adenosine receptor subtypes is required to maximize the pos-
sibilities of adenosine-related therapeutics translating to
clinical improvements in patient care.References
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